Summary. Insulin resistance is present in patients suffering from lipoatrophic syndromes long before the onset of diabetes mellitus. Thus, the decreased peripheral glucose disposal may not be the only mechanism of hyperglycaemia. The kinetic parameters of glucose homeostasis were evaluated in six young females aged 15,16, 18, 19 and 24 years with generalized lipoatrophy; one patient was studied both at 12 and 15 years. Insulin resistance was evaluated in vivo by the hyperinsulinaemic euglycaemic clamp (3M insulin infusion rates from 1 to 100 mU/kg, min). All patients showed a rightward shift of the dose-response curve, indicating decreased insulin sensitivity. In two patients, maximal glucose disposal was moderately decreased, while in five patients it was dramatically reduced (3.6-6.9 mg/kg, min). Fasting plasma glucose was variable (4.3-18.3 mmol/1) and did not correlate with peripheral glucose disposal rates. Hepatic glucose production, measured by infusion of [6,6-2H] glucose, varied from 1.7 to 8.3 mg/kg, rain and was significantly correlated with fasting plasma glucose. The overproduction of glucose despite basal hyperinsulinism suggested hepatic insulin resistance, which was confirmed by the abnormal response to constant unlabelled glucose infusion (2 mg/kg, min) in five patients. In conclusion, impaired glucose tolerance seems to develop in generalized lipoatrophy with aggravated peripheral insulin resistance. The present data show that fasting hyperglycaemia is mainly the consequence of increased hepatic glucose production.
Generalized lipoatrophy is a syndrome characterized by the total disappearance of subcutaneous adipose tissue [1] . Although rare, it is well defined as a clinical entity among the heterogeneous syndromes of extreme insulin resistance [2] . The generalized absence of fat is usually associated with insulin-resistant diabetes mellitus and hypertriglyceridaemia with consequent hepatomegaly [1] . Insulin resistance generally occurs early in life, mainly as isolated hyperinsulinism [3] . Glucose tolerance gradually deteriorates to reach, often during or after puberty [3] , the state of diabetes with hyperinsulinism and lack of ketosis.
As insulin resistance actually exists long before the onset of diabetes [3] , it may not be the only mechanism underlying the development of sustained hyperglycaemia. In another clinical syndrome, Type 2 (non-insulin-dependent) diabetes, where insulin resistance plays a major role, postabsorptive hyperglycaemia mainly depends on the overproduction of glucose by the liver [4] [5] [6] , and it is not closely correlated with the degree of insulin resistance or insulin-stimulated glucose uptake [7] . Thus, hyperglycaemia may also, at least partly, be the consequence of increased hepatic glucose release in those syndromes where insulin resistance appears as the primary defect. However, as the syndrome of generalized lipoatrophy is extremely rare, this hypothesis has not been tested.
Many studies have clearly documented insulin resistance in vivo in this syndrome [3, [8] [9] [10] [11] [12] [13] [14] [15] [16] , without clearly identifying the organ(s) responsible. In a previous report using the euglycaemic clamp and stable isotope dilution methods along with a panel of in vitro investigations [17] , we demonstrated that insulin resistance concerned not only peripheral glucose disposal, but also hepatic glucose release. However, there appeared to be no correlation between the severity of the hyperglycaemic syndrome and either the degree of peripheral insulin resistance, the rate of hepatic glucose production, or the in vitro alterations at the receptor or the post-receptor levels. We have now extended our study to three new patients and reinvestigated a previously studied individual. These new data demonstrate the predominant role of the liver in the fasting hyperglycaemia found in this extreme insulin-resistant state. 
Subjects and methods

Patients
The patients were six unrelated adolescent females with generalized lipoatrophy. Our previous publication [17] was concerned with three: ZT (19 years old), JB (15 years old) and HD1. HD1 was 12 years old and had moderate hyperglycaemia at the time of the first study; she was examined again at age 15 years (HD2), at which time she had severe hyperglycaemia (Table 1) . DR, who was 18 years old and normoglycaemic, had presented i year earlier with severe hypertriglyceridaemia complicated by acute pancreatitis; she suffered from marked hyperandrogenism with hirsutism, muscular hypertrophy and dysmenorrhea at the time of consultation. ZO was 24 years old and severely hyperglycaemic; she presented with marked hyperandrogenism; her brother has Type 1 (insulindependent) diabetes, and she had been treated with insulin for about 1 year. VV was 16 years old and normoglycaemic; she had been followed since the age of 2 years for lipoatrophy, advanced statural growth, advanced puberty and early and severe signs of hyperandrogenism (hirsutism and dramatic muscular hypertrophy). Two patients were black Africans (JB, HD), two were Indians (DR was from Reunion Island and VV from Martinique), and two were North African Caucasians (ZO, ZT). Four patients (JB, HD, ZO, ZT) had a history of parental consanguinity. All the patients suffered from generalized lipoatrophy, muscular hypertrophy, acanthosis nigricans and moderate hepatomegaly. Abnormalities of carbohydrate metabolism were diagnosed at various ages (Table 1) . Two patients, HD and ZO, 'were treated with insulin, with doses of up to 360 and 390 IU/day, respectively. The insulin treatment was interrupted at least 24 h before the tests. The patients were not taking other medication at the time of the study. Routine blood counts, serum electrolytes, creatinine and liver function tests were within normal limits. All patients were fed a diet containing sufficient amounts of complex carbohydrate before the study.
Seven lean, healthy individuals (five men, two women) with no family history of diabetes, aged 25 + 2 years (22-29 years), were used as a control group. Three different 2-h plateaus were obtained in each subject, using insulin infusion rates from 0.2-5 mU/kg, min. The patients and their parents and individuals in the control group were fully informed of the purpose of the investigation, and they gave their consent to participate. The study was approved by the ethical committee of Necker-Enfants Malades Hospital.
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In vivo methods'
A 3-h oral glucose tolerance test (OGTF; 45 g/m 2) was performed a few days before the protocol described above. Insulin resistance was assessed by the euglycaemic damp technique, using multiple insulin infusion rates [18] . The clamp was performed using an automated glucose-controlled insulin infusion system (Glucose Controller Biostator; Life Science Instruments, Miles Lab. Inc., Elkhart, Ind., USA). The Biostator was connected to the patient in the afternoon preceding the clamp study, as previously described [17] , and plasma glucose was normalized. The insulin infusion rate needed to maintain plasma glucose at normal values during the overnight period helped determine the rates of continuous insulin infusion during the clamp. For the first three patients, it was 1,2 and 10 mU/kg 9 min. For the following studies, it was 5, 10, 20 or 100 mU/kg, min. The rate of glucose infusion was continuously adjusted by the Biostator so as to maintain euglycaemia; values of the last 30 min of each 120-min plateau were used to draw the dose-response curve between plasma insulin levels and glucose infusion rates. Blood samples were taken at 10-min intervals throughout the clamp for determination of plasma free insulin.
Glucose turnover was determined, on another day, by infusion of D-[6,6-ZH]glucose (98 % 2H, CEA, Gif-sur-Yvette, France) while plasma glucose was either normo-or hyperglycaemic, depending on the patient's status. Baseline blood samples were obtained to determine the basal, natural abundance level of isotopic enrichment in plasma glucose. A primed, continuous infusion of [6,6-2H] glucose was then given for 270 min at a rate of 0.04 mg/kg, min, using a calibrated syringe pump (Perfusor IV; B. Braun, Melsungen, Germany). Blood samples were collected between 150 and 180 min of infusion and used to calculate basal hepatic glucose production [19] , while the patient was at a spontaneous postabsorptive plasma glucose level. Unlabelted 10 % dextrose was infused at a rate of 2 mg/kg, rain from 180 to 270 min [20] using a calibrated peristaltic pump. The deuterated glucose enrichment in the plasma between 210 and 270 min was used to evaluate the endogenous glucose production in response to the infusion of exogenous glucose [20] .
All blood samples were immediately centrifuged at 4~ and plasma was separated and kept frozen at -20~ until analysed. The concentrations of glucose in plasma and infusates were measured by the glucose-oxidase method (Autoanalyzer II; Beckman, Fullerton, Calif., USA). Free and total immunoreactive insulin was measured using the method of separation with polyethylene glycol and radioimmunoassay with separation on charcoal (1NSIK-3 CEA kit; CIS Bio International, Gif-sur-Yvette, France). Immunoreactive C-peptide was determined by a double antibody method (RIA-mat C-peptide kit; CIS). The isotopic enrichment of plasma glucose was determined using the butylboronate-acetate derivatives [19] which were analysed by combined gas chromatography-mass spectrometry on a Nermag R1010T instrument (Nermag, Rueil, France). The parameters of glucose kinetics were calculated from steady-state isotope dilution principles [20] . When plasma glucose is in steady state:
where R, is the turnover of glucose, iis the tracer infusion rate, Ei and Ep are the labelled glucose enrichment in the infusate and the plasma, respectively. In the basal state, the turnover of glucose equals the hepatic glucose production. During infusion with unlabelled glucose at a constant rate, ira is equal to the sum of endogenous production and exogenous glucose infusion. Therefore, the hepatic glucose production rate is calculated by subtracting the known rate of infusion of unlabelled glucose from the calculated R,.
Statistical analysis
Data were analysed with correlation coefficients when appropriate.
Results
In vivo studies
The results of the OGTTs for the first three patients have been previously reported [17] . They were clearly abnormal, but varied greatly between patients. OGTTs were not performed on two of the new cases, ZO and HD2, as they were severely hyperglycaemic. (Fig. l) , indicating that less glucose was disposed of by the tissues at comparable plasma insulin levels. In two patients, ZT and HD1, glucose disposal reached 9.0 and 9.2 mg/kg, min respectively with an insulin infusion rate of 10 mU/kg.min (plasma insulin at 3485 and 2330 pmol/1, respectively), while for the healthy subjects the glucose disposal rate was always greater than 12.2 mg/kg-min with insulin infusions of 5 or 10 mU/kg-min. Higher rates were not infused in these, the first two patients. The maximal glucose disposal rate was dramatically reduced to between 3 20 and 4 mg/kg, rain in four cases, and to 6.9 mg/kg-min in one patient, despite insulin infusion rates of up to E 12 100 mU/kg, min. Two of these five patients, ZO and .-HD2, were those with the most severe hyperglycaemia, ~ 10 ebut one was a patient with moderate fasting hypergly-'~ caemia, JB, and two, DR and VV, were normoglycaemic. Thus, there was no correlation between the degree of in-~. sulin resistance for glucose disposal and the postabsorptive plasma glucose levels.
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Conversely, there was a correlation (r = 0.90, p < 0.01) between fasting plasma glucose and basal hepatic glucose production (Fig.2) . Hepatic glucose production was increased despite high fasting plasma insulin and C-peptide levels ( Table 2 ). There was no significant correlation between fasting plasma glucose or hepatic glucose production and either plasma insulin, C-peptide or non-esterified fatty acids, cholesterol and triglycerides (Tables 1 and 2 ).
Hepatic glucose production was 2 mg/kg.min lower than in the basal state in only one patient, during the infusion of glucose at 2 mg/kg, min. In the other patients, in- cluding the two with normoglycaemia, it was less suppressed ( Table 2) . The extent to which hepatic glucose production was suppressed did not correlate with fasting plasma glucose, basal hepatic glucose production or plasma insulin levels. Plasma insulin and C-peptide remained close to the basal level during glucose infusion; insulin increased from 384 +79 (mean + SEM) to 411 + 78 pmol/1 and C-peptide from 1012 + 236 to 1147 + 253 pmol/1.
Discussion
Our previous report on three patients with generalized lipoatrophy [17] , indicated insulin resistance at several organ sites: muscle, liver and islet beta cells. The inclusion of three more patients and the reinvestigation of a previously studied individual has given a much clearer picture of the mechanisms of hyperglycaemia in these syndromes of insulin resistance. The hyperinsulinaemic euglycaemic clamp showed marked insulin resistance in all patients, with a rightward shift of the dose-response curve between plasma insulin levels and glucose disposal rates. However, two of the six patients had a slightly decreased capacity to utilize glucose; they were normo-and moderately hyperglycaemic in the postabsorptive state. Two other patients, who were comparable to the first two in terms of fasting blood glucose, glucose intolerance and HbAlc, had a very low maximal capacity for glucose disposal, even at very high plasma insulin concentrations. Finally, two patients were severely hyperglycaemic and extremely insulin resistant. One patient, who was studied twice with a 3-year interval, developed hyperglycaemia while insutin resistance had greatly increased. Although these observations suggest that hyperglycaemia and peripheral insulin resistance may develop concomitantly, fasting plasma glucose varied greatly for the same severity of insulin resistance.
Conversely, plasma glucose was strongly correlated with the rate of hepatic glucose production. As reported previously [17] , there was no detectable difference between normo-and moderately hyperglycaemic patients. This is not surprising, since variations of hepatic glucose production in the 5-10 mmol/1 range have been shown to be small in other types of diabetes. They are less than the inter-individual variations and can be identified only by comparing the same individual at different plasma glucose levels [21] . Correlations with hepatic glucose production become readily measurable only when the plasma glucose levels are higher than approximately 10 mmol/1 [4] [5] [6] 21] .
Although these observations were made on a small number of subjects, they are in agreement with other studies of rare individuals with generalized lipoatrophy. Increased hepatic glucose production has been correlated with fasting hyperglycaemia in two patients [13, 14] , and in one it returned to normal along with the normalization of glycaemia following dietary and insulin therapy [13] . In a recent study of another type of extreme insulin resistance with acanthosis nigricans, four patients with diabetes had much greater hepatic glucose production than did the non-diabetic patients, while the peripheral insulin resistance was only slightly greater [16] . This suggests that the fasting plasma glucose level does not depend primarily on the severity of peripheral insulin resistance in these syndromes of extreme insulin resistance. Insulin resistance is principally responsible for the postprandial glucose intolerance. Diabetes develops permanently as a consequence of increased production of glucose by the liver, which occurs despite high circulating insulin levels.
The predominant role of hepatic glucose production in the development of hyperglycaemia in the other types of diabetes has been well established. The overproduction of glucose is completely responsible for the fasting hyperglycaemia in Type 1 diabetes [21] . It has also been shown that hepatic insulin resistance, as manifested by alterations in glucose production, may be the predominant factor contributing to fasting hyperglycaemia in Type 2 diabetes [5, 6] . In the syndromes of extreme insulin resistance, such as generalized lipoatrophy, fasting hyperglycaemia seems to develop following the same alterations in the kinetic parameters of glucose metabolism, although the primary mechanisms are different.
However, the present observations clearly show that the relationship between insulin resistance at the hepatic and peripheral levels is not as simple as that seen in Type 2 diabetes [6] . Patients with the same extreme peripheral insulin resistance showed varying capacities to control hepatic glucose output. In addition, the levels of circulating insulin required to maintain the fasting plasma glucose at normal levels varied greatly, as did the response of hepatic glucose production to increased endogenous insulin secretion caused by the infusion of a low dose of glucose. None of these various parameters were correlated. In addition, differences in the lipid status of the patients did not seem to be related to the peripheral insulin resistance or hepatic glucose production.
In vitro studies, performed in the six patients, are in good agreement with results published previously [17, 22, 23] . The four patients who had never been treated with insulin had no insulin autoantibodies, and none had insulin receptor autoantibodies. Insulin binding, studied on erythrocytes and on skin fibroblasts in primary cultures, was either normal (VV, HD1, JB, ZT and ZO) or about 50 % sub-normal (DR). At the post-binding level, there were alterations in the tyrosine kinase activity for all patients, concerning either the autophosphorylation process or the exogenous tyrosine kinase activity or both [23] . Similar conclusions were drawn concerning the post-receptor insulin action on glucose metabolism (hexose transport or glycogen synthesis), while the activation of amino acid transport by insulin was unaffected [22] . Thus, defects were present at the cellular level, resulting in insulin resistance in vitro in all cases. The genetic defects responsible for this resistance are still unknown [24, 25] . The pattern and extent of the alterations were heterogeneous both in vivo and in vitro. However, there were no clear correlations between the in vivo and the in vitro data. This is not surprising, since in vivo results partly reflect alterations secondary to the metabolic and hormonal status [26, 27] . This was clearly shown for the patient who was studied on two occasions. Insulin resistance was moderate and insulin binding to erythrocytes was normal during the first study. During the second investigation, when fasting blood glucose had dramatically worsened, both parameters were markedly impaired.
In conclusion, although we have shown that the biological expression of insulin resistance at its various sites appears to be variable, the nature of their interrelationships should be further explored to provide a clearer picture of the progressive development of hyperglycaemia in syndromes of extreme insulin resistance, such as generalized lipoatrophy.
